Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/8175 |
Resumo: | Recent studies show a strong relationship between the use of hydrochlorathiazide (diuretic and antihypertensive drug) and the risk of developing melanoma due to its photosensitizing feature on the skin. The aim of this paper is to show the association between the use of hydrochlorathiazide and the increased risk of melanoma onset. The methodology was a bibliographic survey with articles published from 2016 to 2019 in the electronic databases of scientific reliability PubMed, Medline, Science Direct and journals specialized in the subject. Four pertinent studies were found on the subject, which identified that hydrochlorothiazide is classified as a carcinogenic drug by the International Agency for Research on Cancer. As exposure to ultraviolet light increases skin cell damage, long-term concomitant administration of hydrochlorothiazide leads to an increased likelihood of skin malignancy, including the development of melanoma. A meta-analysis was performed involving melanoma patients in Denmark. The total study population was 19,273 cases and 192,730 controls; Among these, 413 cases (2.1%) and 3,406 controls (1.8%) were classified as users of high cumulative doses of hydrochlorothiazide (≥ 50,000 mg), resulting in an adjusted odds ratio (OR) of 1.22 for melanoma. Therefore, it is suggested that the use of hydrochlorothiazide is associated with the onset of melanoma. More large studies, mainly national, are needed to confirm the findings. Therefore, the indication that hydrochlorothiazide use increases the risk of melanoma may have clinical relevance related to drug choice, particularly for patients with melanoma risk factors. |
id |
UNIFEI_bb63c58b2ed62679d6758fbf1188ece6 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/8175 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature reviewRelación del uso extendido de hidroclorotiazida con melanoma: revisión de la literaturaRelação do uso prolongado de hidroclorotiazida com o melanoma: uma revisão de literaturaMelanoma; Hydrochlorothiazide; Association; Risk.MelanomaHidroclorotiazidaAssociaçãoRiscoMelanoma; Hidroclorotiazida; Asociación; Riesgo.Recent studies show a strong relationship between the use of hydrochlorathiazide (diuretic and antihypertensive drug) and the risk of developing melanoma due to its photosensitizing feature on the skin. The aim of this paper is to show the association between the use of hydrochlorathiazide and the increased risk of melanoma onset. The methodology was a bibliographic survey with articles published from 2016 to 2019 in the electronic databases of scientific reliability PubMed, Medline, Science Direct and journals specialized in the subject. Four pertinent studies were found on the subject, which identified that hydrochlorothiazide is classified as a carcinogenic drug by the International Agency for Research on Cancer. As exposure to ultraviolet light increases skin cell damage, long-term concomitant administration of hydrochlorothiazide leads to an increased likelihood of skin malignancy, including the development of melanoma. A meta-analysis was performed involving melanoma patients in Denmark. The total study population was 19,273 cases and 192,730 controls; Among these, 413 cases (2.1%) and 3,406 controls (1.8%) were classified as users of high cumulative doses of hydrochlorothiazide (≥ 50,000 mg), resulting in an adjusted odds ratio (OR) of 1.22 for melanoma. Therefore, it is suggested that the use of hydrochlorothiazide is associated with the onset of melanoma. More large studies, mainly national, are needed to confirm the findings. Therefore, the indication that hydrochlorothiazide use increases the risk of melanoma may have clinical relevance related to drug choice, particularly for patients with melanoma risk factors.Estudios recientes indican una fuerte relación entre el uso de hidroclorotiazida (fármaco diurético y antihipertensivo) con el riesgo de desarrollar melanoma debido a su característica fotosensibilizante en la piel. El objetivo de este estudio es mostrar la asociación entre el uso de hidroclorotiazida y el aumento del riesgo de melanoma. La metodología fue una encuesta bibliográfica con artículos publicados en el período de 2016 a 2019 en las bases de datos electrónicas de confiabilidad científica PubMed, Medline, Science Direct y revistas especializadas en el tema. Se encontraron cuatro estudios pertinentes sobre el tema, donde se identificó que la hidroclorotiazida está clasificada como un fármaco cancerígeno por la Agencia Internacional para la Investigación del Cáncer. Como la exposición a la luz ultravioleta aumenta el daño de las células de la piel, la administración concomitante a largo plazo de hidroclorotiazida aumenta la probabilidad de malignidad de la piel, incluido el desarrollo de melanoma. La población total del estudio fue de 19 273 casos y 192 730 controles; entre estos, 413 casos (2,1%) y 3,406 controles (1,8%) se clasificaron como usuarios de dosis acumuladas altas de hidroclorotiazida (≥ 50 000 mg), lo que resultó en una razón de posibilidades (OR) ajustada de 1,22 para el melanoma. Por tanto, se sugiere que el uso de hidroclorotiazida se asocia con la aparición de melanoma. Se necesitan estudios más amplios, principalmente nacionales, para confirmar los hallazgos. Por lo tanto, la indicación de que el uso de hidroclorotiazida aumenta el riesgo de melanoma puede tener relevancia clínica relacionada con la elección del fármaco, particularmente para pacientes con factores de riesgo de melanoma.Estudos recentes apontam forte relação entre o uso da hidrocloratiazida (droga diurética e anti-hipertensiva) com o risco de desenvolver melanoma devido a sua característica fotossensibilizadora sobre a pele. O objetivo desse trabalho é evidenciar a associação entre o uso de hidrocloratiazida e o aumento do risco de aparecimento do melanoma. A metodologia foi um levantamento bibliográfico com artigos publicados no período de 2016 a 2019 nas bases de dados eletrônicos de confiabilidade científica PubMed, Medline, Science Direct e revistas especializados no assunto. Foram encontrados 4 estudos pertinentes sobre o tema, onde identificou-se que a hidroclorotiazida é classificada como um medicamento carcinogênico pela Agência Internacional de Pesquisa sobre o Câncer. À medida que a exposição à luz ultravioleta aumenta os danos das células da pele, a administração concomitante a longo prazo da hidroclorotiazida conduz a um aumento da probabilidade de malignidade cutânea, incluindo o desenvolvimento de melanoma. A população total do estudo foi de 19.273 casos e 192.730 controles; entre esses, 413 casos (2,1%) e 3.406 controles (1,8%) foram classificados como usuários de altas doses cumulativas de hidroclorotiazida (≥ 50.000 mg), resultando em odds ratio (OR) ajustado de 1,22 para melanoma. Portanto, sugere-se que o uso de hidroclorotiazida está associado ao aparecimento de melanoma. Mais estudos de grandes proporções, principalmente nacionais, são necessários para confirmar os achados. Portanto, a indicação de que o uso de hidroclorotiazida aumenta o risco de melanoma pode ter relevância clínica relacionada à escolha medicamentosa, particularmente para pacientes com fatores de risco para melanoma.Research, Society and Development2020-09-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/817510.33448/rsd-v9i9.8175Research, Society and Development; Vol. 9 No. 9; e958998175Research, Society and Development; Vol. 9 Núm. 9; e958998175Research, Society and Development; v. 9 n. 9; e9589981752525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/8175/7242Copyright (c) 2020 André Chaves Calabria; Claudia Spaniol; Graziela Társis Araujo Carvalho; Luana Limas de Souzahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessChaves Calabria, AndréSpaniol, ClaudiaTársis Araujo Carvalho, GrazielaLimas de Souza, Luana2020-09-18T01:42:11Zoai:ojs.pkp.sfu.ca:article/8175Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:30:42.479094Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review Relación del uso extendido de hidroclorotiazida con melanoma: revisión de la literatura Relação do uso prolongado de hidroclorotiazida com o melanoma: uma revisão de literatura |
title |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review |
spellingShingle |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review Chaves Calabria, André Melanoma; Hydrochlorothiazide; Association; Risk. Melanoma Hidroclorotiazida Associação Risco Melanoma; Hidroclorotiazida; Asociación; Riesgo. |
title_short |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review |
title_full |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review |
title_fullStr |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review |
title_full_unstemmed |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review |
title_sort |
Relationship of the extended use of hydrochlorothiazide with melanoma: a literature review |
author |
Chaves Calabria, André |
author_facet |
Chaves Calabria, André Spaniol, Claudia Társis Araujo Carvalho, Graziela Limas de Souza, Luana |
author_role |
author |
author2 |
Spaniol, Claudia Társis Araujo Carvalho, Graziela Limas de Souza, Luana |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Chaves Calabria, André Spaniol, Claudia Társis Araujo Carvalho, Graziela Limas de Souza, Luana |
dc.subject.por.fl_str_mv |
Melanoma; Hydrochlorothiazide; Association; Risk. Melanoma Hidroclorotiazida Associação Risco Melanoma; Hidroclorotiazida; Asociación; Riesgo. |
topic |
Melanoma; Hydrochlorothiazide; Association; Risk. Melanoma Hidroclorotiazida Associação Risco Melanoma; Hidroclorotiazida; Asociación; Riesgo. |
description |
Recent studies show a strong relationship between the use of hydrochlorathiazide (diuretic and antihypertensive drug) and the risk of developing melanoma due to its photosensitizing feature on the skin. The aim of this paper is to show the association between the use of hydrochlorathiazide and the increased risk of melanoma onset. The methodology was a bibliographic survey with articles published from 2016 to 2019 in the electronic databases of scientific reliability PubMed, Medline, Science Direct and journals specialized in the subject. Four pertinent studies were found on the subject, which identified that hydrochlorothiazide is classified as a carcinogenic drug by the International Agency for Research on Cancer. As exposure to ultraviolet light increases skin cell damage, long-term concomitant administration of hydrochlorothiazide leads to an increased likelihood of skin malignancy, including the development of melanoma. A meta-analysis was performed involving melanoma patients in Denmark. The total study population was 19,273 cases and 192,730 controls; Among these, 413 cases (2.1%) and 3,406 controls (1.8%) were classified as users of high cumulative doses of hydrochlorothiazide (≥ 50,000 mg), resulting in an adjusted odds ratio (OR) of 1.22 for melanoma. Therefore, it is suggested that the use of hydrochlorothiazide is associated with the onset of melanoma. More large studies, mainly national, are needed to confirm the findings. Therefore, the indication that hydrochlorothiazide use increases the risk of melanoma may have clinical relevance related to drug choice, particularly for patients with melanoma risk factors. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-09-14 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/8175 10.33448/rsd-v9i9.8175 |
url |
https://rsdjournal.org/index.php/rsd/article/view/8175 |
identifier_str_mv |
10.33448/rsd-v9i9.8175 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/8175/7242 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 9 No. 9; e958998175 Research, Society and Development; Vol. 9 Núm. 9; e958998175 Research, Society and Development; v. 9 n. 9; e958998175 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052658937233408 |